Herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis

ABSTRACT

The present invention relates to a herbal mixture extract of  Rehmanniae  Radix Preparata and  Acanthopanacis  Cortex and a composition comprising the same for the prevention and treatment of osteoporosis. The herbal mixture extract of the present invention enhances the expression of osteoprotegerin (OPG) in osteoblasts and effectively inhibits the generation and activation of osteoclasts, so that it can be effectively used for the prevention and treatment of osteoporosis.

TECHNICAL FIELD

The present invention relates to a herbal mixture extract of RehmanniaeRadix Preparata and Acanthopanacis Cortex and a composition containingthe same as an effective ingredient for the prevention and treatment ofosteoporosis.

BACKGROUND ART

Bone is calcified connective tissue joined to muscle, which has hard andthick calcified surface, carries out the function of supporting body bykeeping balance and protects organs. The inner bone marrow is myeloidtissue playing a key role in calcium metabolism. Bone is composed oforganic substances such as collagen, osteocalcin and osteonectin,inorganic substances such as calcium, phosphorus and fluorine and water.Bone formation and bone resorption are necessary daily processes invivo. Bone formation is stimulated by low dose of parathyroid hormone,androgen, estrogen, fluorine, phosphorus, etc and bone resorption isstimulated by physical decompression, a gravity, a high dose ofparathyroid hormone and adrenocortical steroid, etc. Thus, bonemetabolism is regulated by the balance between bone formation and boneresorption.

Osteoporosis is caused by unbalance between bone formation and boneresorption. Precisely, osteoporosis progresses when bone resorptionoutraces bone formation. With osteoporosis, calcified bone tissuedensity decreases and thus compact substance of bone is lost gradually,leading to the expansion of marrow cavity. As symptoms progress, whichmeans bone loss is increasing, fracture occurs frequently even with aminimum impulse. Bone tissue is a dynamic tissue which is designed tocarry out repeatedly bone formation by osteoblasts and destroy and boneresorption by osteoclasts.

Bone resorption is processed by osteoclasts and a receptor activator ofNF-B receptor (RANKL) is essential for the generation and activation ofosteoclasts. RANKL exists in osteoblasts and mesenchymal cells and isbound to a receptor activator of NF-B receptor (RANK) [Hofbauer L. C.,Khosla S., Dunstan C. R., Lacey D. L., Boyle W. J., Riggs B. L., Theroles of osteoprotegerin and osteoprotegerin ligand in the paracrineregulation of bone resorption. J Bone Miner Res., 15(1):2-12, 2000].Osteoprotegerin (OPG), produced in osteoblasts, acts as a decoy receptorof RANKL to intercept the binding of RANKL and RANK, resulting in theinhibition of differentiation of osteoclast precursors into osteoclastsand activation of osteoclasts [Kong Y. Y., Feige U., Sarosi I., BolonB., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S.,Wong T., Campagnuolo G., Moran E., Bogoch E. R., Van G., Nguyen L. T.,Ohashi P. S., Lacey D. L., Fish E., Boyle W. J., Penninger J. M.:Activated T cells regulate bone loss and joint destruction in adjuvantarthritis through osteoprotegerin ligand. Nature, 402:304-309, 1999;Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M. T., Martin T.J.: Modulation of osteoclast differentiation and function by the newmembers of the tumor necrosis factor receptor and ligand families.Endocr Rev, 20(3):345-357, 1999; Aubin J. E., Bonnelye E.:Osteoprotegerin and its ligand: a new paradigm for regulation ofosteoclastogenesis and bone resorption. Osteoporos Int, 11(11):905-913,2000].

Osteoporosis is divided into primary and secondary types; primaryosteoporosis is exemplified by senile osteoporosis and post menopausalosteoporosis, and secondary osteoporosis is developed as a complicationof hyperthyroidism, hyperparathyroidism, hyperadrenocorticism,pregnancy, prolonged fixation (for example, plaster cast fixation),malnutrition, drugs, cancer or other chronic diseases.

The cause of primary osteoporosis has not been disclosed, yet variousfactors seem to be involved. It is assumed that osteoporosis isdeveloped by unbalance of bone metabolism by aging, calcium deficiency,excessive parathyroid hormone, calcitonin deficiency, active vitamin Ddeficiency, estrogen deficiency, insufficient exercise, etc. Factorsaffecting calcium metabolism are parathyroid hormone (PTH), calcitonin(CT) and 1,25-(OH)₂D₃, etc. Parathyroid hormone involved in calciummetabolism counter acts calcitonin secreted in C-cells, parafollicularcells of thyroid gland. As a polypeptide, calcitonin having a molecularweight of 3,500˜4,000 mediates the deposition of calcium salts in bone.That is, calcitonin reduces blood calcium and magnesium, and phosphateand hydroxyproline in urine. Parathyroid hormone (PTH) is also apolypeptide having molecular weight of 8447. Parathyroid hormoneactivates osteoclasts, resulting in the increase of bone resorption andactivity of vitamin D₃ in small intestinal mucosa. So, PTH increasesblood calcium and magnesium, and hydroxyproline and phosphate (PO₄ ³—)in urine. Estradiol, asteroid secreted in ovary, activates osteoblastsin bone, thereby inhibits bone resorption.

Post menopausal women exhibit lower level of estrogen, and as a result,the level of blood calcitonin as well as l, 25-(OH)₂D₃ synthesis inkidney is reduced, while the level of PTH is elevated. Accordingly,productions of interleukin 6 (IL-6) and prostaglandin are promoted,resulting in the decrease of calcium absorption in small intestine andthe increase of bone loss by active osteoclast mediated bone resorption.As a result, osteoporosis is developed. In general, when bone resorptionoutpaces bone formation, joint dysfunction, gradual vertebralmalformation, minor fracture in vertebra and other regions, loweredmobility by pain (in particular lumbo-dorsal pain) and contracted kidneyby kyphosis are observed.

Osteoporosis is characterized more by bone decrease in amount leading tofractures including femur fracture or vertebral fracture than by itssymptoms, and has been a public health problem limiting publicactivities for long-term. So, 15% of causes of death of the aged areattributed to osteoporosis. Bone density is affected by genetic factors,nutrition, hormone changes, exercise and habits. Aging, insufficientexercise, low weight, smoking, low calcium diet, menopause andovariectomy are known as major causes of osteoporosis.

In the meantime, it is known that black people exhibit lower boneresorption level than white people, meaning black people have biggerbone mass. The peak bone mass is observed between age 14 and 18, andthen reduces 1% per year. Inparticular, bone is continuously decreasedfrom the age of 30 in women, and is rapidly reduced after menopause byhormone change.

Osteoporosis, more or less, is inevitable in the aged, especially inpost menopausal women, so osteoporosis and its therapeutic agent havebeen in the center of our concern as an aging population grows inadvanced countries.

The treatment of bone diseases forms approximately 130 billiondollar-market throughout the world, which is assumed to be growingfurther. Thus, numbers of research teams and pharmaceutical companieshave invested to develop a therapeutic agent for bone diseases and aninhibitor for bone resorption.

Osteoporosis-related studies have been focused on inorganic substancesin bone, specifically on calcium and phosphorus metabolism, so far.However, concrete pathogenic mechanism has not been disclosed, yet.

A therapeutic agent for osteoporosis being used today is exemplified bybisphosphonate products (alendronate, etidronate), hormone products(raloxifene), vitamin D products, calcitonin products and calciumproducts, etc. However, bisphosphonate products have problems of lowabsorption rate, troublesome administration methods and inducingesophagitis. Hormone products require life-time administration, whichhas possibility of carrying side effects such as breast cancer, uterinecancer, cholelithiasis and thrombosis, etc. Vitamin D products areexpensive but not much effective. Calcitonin products have also problemsof high costs and hard administration. Calcium products have less sideeffects but are limited to rather prevention than treatment.

Short-term administration of a drug is not much effective for thetreatment of osteoporosis, and thus long-term administration of a drugis inevitable. Therefore, a novel agent having less side effects butmore medicinal effects is required for long-term administration.

The present inventors, thus, have studied on various physiologicalactivities of Rehmanniae Radix Preparata and Acanthopanacis Cortex. Andthe inventors finally completed the present invention by confirming thata herbal mixture extract of Rehmanniae Radix Preparata andAcanthopanacis Cortex has no toxicity, enhances the expression ofosteoprotegerin, a protein inhibiting generation and activation ofosteoclasts, and suppresses osteoclast proliferation, so that themixture can be effectively used for the prevention and treatment ofosteoporosis.

DISCLOSURE

[Technical Problem]

It is an object of the present invention to provide a herbal mixtureextract of Rehmanniae Radix Preparata and Acanthopanacis Cortex havingactivities of promoting the expression of osteoprotegerin (OPG) inosteoblasts and inhibiting the generation of osteoclasts.

It is another object of the present invention to provide a compositionfor the prevention and treatment of osteoporosis containing the herbalmixture extract as an effective ingredient.

[Technical Solution]

To achieve the above object, the present invention provides a herbalmixture extract of Rehmanniae Radix Preparata and Acanthopanacis Cortexhaving activities of promoting the expression of osteoprotegerin (OPG)in osteoblasts and inhibiting the generation of osteoclasts.

Also, the present invention provides a composition for the preventionand treatment of osteoporosis containing the herbal mixture extract asan effective ingredient.

DESCRIPTION OF DRAWINGS

The application of the preferred embodiments of the present invention isbest understood with reference to the accompanying drawings, wherein:

FIG. 1 is a graph showing the expression of OPG in an osteoblast cellline MG63 treated with the herbal mixture extract according to anembodiment example of the present invention detected by ELISA,

FIG. 2 is a graph showing the inhibition of osteoclast generation by theherbal mixture extract according to an embodiment example of the presentinvention.

BEST MODE

Hereafter, the present invention is described in detail.

The present invention provides a herbal mixture extract of RehmanniaeRadix Preparata and Acanthopanacis Cortex having activities of promotingthe expression of osteoprotegerin (OPG) in osteoblasts and inhibitingthe generation of osteoclasts.

Rehmanniae Radix Preparata is a root of a medicinal plant belonging toScrophulariaceae, which has been used as a traditional oriental medicineafter being steamed and dried. The raw Rehmanniae Radix Preparata iscalled Rehmanniae radix crudus Libosch, and the dried Rehmanniae RadixPreparata is called Rehmanniae Radix Libosch. In particular, the onewhich has been through steam-dry processes after being dipped in alcoholnine times is called ‘Gujihwang’, whose medicinal effect is known as thebest. It has sweet and bitter taste at the same time and has property ofmaking things warm, by which it can supplement blood and energy (a basicsubstance necessary for the life and vital activity) so that it helpsthe treatment of the coldness of knees and lower back and menstrualirregularity, in addition to making hair black and healthy. RehmanniaeRadix Preparata is one of major components for Samultang and has beenadministered for relieving fever, dried throat and dipsesis, symptoms ofbeing weak. Besides, it has been known in folk remedies that RehmanniaeRadix Preparata shows therapeutic effect on constipation when it isadministered together with pork soup.

Acanthopanacis Cortex is a shrub belonging to Araliaceae, which is onlyfound in far-east Asia in northern hemisphere. In particular,Acanthopanacis Cortex is classified as a reserved wild plant in SouthKorea, which is on the brink of extinction. Acanthopanacis Cortex isdivided into Acanthopanax senticosus, Acanthopanax and Acanthopanaxkoreanum. The roots and barks of Acanthopanacis cortex have been used astop-ranked medicine since they have not shown any toxicity or sideeffects so far. The leaf of Acanthopanacis cortex contains chilsanoside,which has pharmaceutical effect. The roots of Acanthopanacis Cortexcontain not only Acanthopanacis Cortex glycoside but also syringin andcoumarin glycosides. Acanthopanacis Cortex contains acanthosides B andD, which are Acanthopanacis Cortex glycosides, and water-solublepolysaccharides enhancing immunity. Its' taste is bitter and hot and ithas a property of warming things up. It is known to eliminate gout inliver and nervous systems, invigorate and bring essence in a body. Ithas been prescribed for such diseases as Oro (fatigue caused by theweakness of five internal organs), Chilsang (seven representativesymptoms shown in men caused by the weakness of a body) and difficultyin moving legs. Long-term administration of Acanthopanacis Cortexincreases energy, protects the stomach, invigorates, clears mind,increases will power, prevents aging, helps having a light heart andclear the blood in a body. So, Acanthopanacis Cortex has been used forthe treatment of such symptoms as pain in backbone, male impotence,scrotal eczema, female amenorrhea, etc.

The herbal mixture extract of Rehmanniae Radix Preparata andAcanthopanacis Cortex of the present invention is extracted using mixedsolution of Rehmanniae Radix Preparata and Acanthopanacis Cortex withwater, C₁˜C₄ alcohol or the mixture of water and C₁˜C₄ alcohol, and morepreferably using water. The herbal mixture extract is prepared asfollows.

Rehmanniae Radix Preparata and Acanthopanacis Cortex are washedthoroughly with water and dried in the shadow. They are put in anextraction vessel, to which a solvent is added, followed by extraction.The extract is cooled down at room temperature, followed by filteringwith a filter paper. Then, the extract is concentrated under reducedpressure by using vacuum rotation evaporator, followed by freeze-drying.As a result, powder type Rehmanniae Radix Preparata and AcanthopanacisCortex extracts are respectively prepared. The two extracts ofRehmanniae Radix Preparata and Acanthopanacis Cortex are mixed toprepare a herbal mixture extract.

Extraction can be performed by the conventional methods such asmaceration, infusion and heat extraction by using a proper solvent, andin particular hot water extraction at 100° C. for 4 hours is preferred.

And, it is preferred for the herbal mixture extract that RehmanniaeRadix Preparata extract and Acanthopanacis Cortex extract are mixed atthe weight ratio of 15.0:0.5˜0.15:5.0, and is more preferred to be mixedat the ratio of 8:1˜1:4. It is most preferred to mix Rehmanniae RadixPreparata extract and Acanthopanacis Cortex extract at the weight ratioof 4:1˜1:1.

The herbal mixture extract of the present invention enhances theexpression of osteoprotegerin which inhibits the generation andactivation of osteoclasts (FIG. 1).

The herbal mixture extract of the present invention has an effect ofinhibiting the generation of osteoclasts (FIG. 2).

The outstanding promoting effect on the expression of osteoprotegerin inosteoblasts and inhibiting effect on the generation of osteoclasts areobserved when the herbal mixture extract of Rehmanniae Radix Preparataextract and Acanthopanacis Cortex is prepared at the weight ratio of8:1˜1:4 and more preferably at the weight ratio of 4:1˜1: 1. When thetwo components are mixed together, the above effects are greater thanwhen each extract is used independently.

The herbal mixture extract of the present invention has activities ofenhancing the expression of osteoprotegerin inhibiting the generationand activation of osteoclasts and suppressing the generation ofosteoclasts, so that it can be effectively used as a composition for theprevention and treatment of osteoporosis.

The herbal mixture extract of the present invention was orallyadministered to rats to investigate toxicity. As a result, it wasevaluated to be safe substance since its estimated LD₅₀ value (50%lethal dose) is much greater than 1 g/kg in rats.

The present invention also provides a composition for the prevention andtreatment of osteoporosis containing the above herbal mixture extract asan effective ingredient.

The composition of the present invention can additionally include, inaddition to the herbal mixture extract, one or more effectiveingredients having the same or similar functions to the extract of theinvention.

The herbal mixture extract of the present invention can be administeredorally or parenterally and be used in general forms of pharmaceuticalformulation.

The herbal mixture extract of the present invention can be prepared fororal or parenteral administration by mixing with generally used fillers,extenders, binders, wetting agents, disintegrating agents, diluents suchas surfactant, or excipients. Solid formulations for oral administrationare tablets, pills, dusting powders, granules and capsules. These solidformulations are prepared by mixing one or more suitable excipients suchas starch, calcium carbonate, sucrose, lactose, gelatin, etc. Except forthe simple excipients, lubricants, for example magnesium stearate, talc,etc, can be used. Liquid formulations for oral administrations aresuspensions, solutions, emulsions and syrups, and the above mentionedformulations can contain various excipients such as wetting agents,sweeteners, aromatics and preservatives in addition to generally usedsimple diluents such as water and liquid paraffin. Formulations forparenteral administration are sterilized aqueous solutions,water-insoluble excipients, suspensions, emulsions, and suppositories.Water insoluble excipients and suspensions can contain, in addition tothe active compound or compounds, propylene glycol, polyethylene glycol,vegetable oil like olive oil, injectable ester like ethylolate, etc.Suppositories can contain, in addition to the active compound orcompounds, witepsol, macrogol, tween 61, cacao butter, laurin butter,glycero gelatin, etc. In addition, calcium or vitamin D₃ can be includedto enhance the preparative or therapeutic effect on osteoporosis.

The effective dosage of the composition can be determined according toweight, age, gender, health condition, diet, administration frequency,administration method, excretion and severity of a disease. The dosageof the composition is 1˜1000 mg/kg per day, and preferably 300˜700 mg/kgper day. More preferably, the dosage is 150˜450 mg/kg per day.Administration frequency is 1˜6 times a day.

The composition of the present invention can be administered singly ortreated along with surgical operation, hormone therapy, chemotherapy andbiological reaction regulator, to prevent and treat osteoporosis.

The composition of the present invention can be included in health foodfor the purpose of alleviating symptoms of osteoporosis. At this time,the herbal mixture extract of the present invention can be added as itis or after being mixed with other food or ingredients, according to theconventional method. The mixing ratio of effective ingredients isdetermined by the purpose of use (prevention, health or therapeutictreatment).

There is no limit in applicable food, which is exemplified by meats,sausages, bread, chocolate, candies, snacks, cookies, pizza, ramyun,noodles, dairy products including ice cream, soups, beverages, tea,drinks, alcoholic drinks and vitamin complex, etc, and in fact everyhealth food generally produced are all included.

Health beverages containing the composition of the present invention canadditionally include various flavors or natural carbohydrates, etc, likeother beverages. The natural carbohydrates above can be one ofmonosaccharide such as glucose and fructose, disaccharides such asmaltose and sucrose, polysaccharides such as dextrin and cyclodextrin,and sugar alcohols such as xylitol, sorbitol and erythritol. As asweetener, either natural sweetener such as thaumatin and stevia extractor artificial sweetener such as saccharin and aspartame can be used. Theratio of natural carbohydrate to the composition of the presentinvention is preferably 0.01˜0.04 g to 100 ml, more preferably 0.02˜0.03g to 100 ml.

In addition to the ingredients mentioned above, the composition of thepresent invention can include in variety of nutrients, vitamins,electrolytes, flavoring agents, coloring agents, pectic acid and itssalts, arginic acid and its salts, organic acid, protective colloidalviscosifiers, pH regulators, stabilizers, antiseptics, glycerin,alcohols, carbonators which used to be added to soda, etc. Thecomposition of the present invention can also include natural fruitjuice, fruit beverages and/or fruit flesh addable to vegetablebeverages. All the mentioned ingredients can be added singly ortogether. The mixing ratio of those ingredients does not matter in fact,but in general, each can be added by 0.01˜0.1 weight part per 100 weightpart of the composition of the invention.

MODE FOR INVENTION

Practical and presently preferred embodiments of the present inventionare illustrative as shown in the following Examples.

However, it will be appreciated that those skilled in the art, onconsideration of this disclosure, may make modifications andimprovements within the spirit and scope of the present invention.

EXAMPLE 1 Preparation of Herbal Extracts

Cultivated Rehmanniae Radix Preparata and Acanthopanacis Cortex werepurchased from a wholesale dried medicinal herb store.

<1-1> Preparation of Rehmanniae Radix Preparata Extract

Rehmanniae Radix Preparata was washed with clean water and dried in theshadow. 100 g of the dried Rehmanniae Radix Preparata was put in a 3 lextraction vessel, to which 1 l of distilled water was added, followedby hot water extraction for 4 hours at 100□. The process was repeatedthree times, and the resultant solution was cooled down at roomtemperature, followed by filtering with a filter paper. The extractedsolution was concentrated under reduced pressure under 40° C. by usingvacuum rotary evaporator. As a result, Rehmanniae Radix Preparataextract was obtained (yield: 42%).

<1-2>Preparation of Acanthopanacis Cortex Extract

Acanthopanacis Cortex was washed with clean water and dried in theshadow. 100 g of the dried Acanthopanacis Cortex was put in a 3 lextraction vessel, to which 1 l of distilled water was added, followedby hot water extraction for 4 hours at 100□. The process was repeatedthree times, and the resultant solution was cooled down at roomtemperature, followed by filtering with a filter paper. The extractedsolution was concentrated under reduced pressure under 40° C. by usingvacuum rotary evaporator, followed by freeze-drying. As a result, powderextract of Acanthopanacis Cortex was obtained (yield: 5.8%).

<1-3> Preparation of Herbal Mixture Extract

0.15˜15.0 weight part of Rehmanniae Radix Preparata extract obtained inExample 1-1 and 0.5˜5.0 weight part of Acanthopanacis Cortex extractobtained in Example <1-2> were mixed at a proper ratio, and the herbalmixture extract was diluted in cell culture medium to be used forfurther experiments.

EXPERIMENTAL EXAMPLE 1 Effect of Herbal Mixture Extract of the PresentInvention on the Expression of Osteoprotegerin in Osteoblasts

Following experiments were performed to investigate the effect of herbalmixture extract of the present invention on the expression ofosteoprotegerin in osteoblasts.

<1-1> Culture of Osteoblasts

To evaluate the effect of the herbal mixture extract of the invention onthe expression of osteoprotegerin in osteoblasts, human osteosarcomacell lines MG-63 and HOS were purchased from ATCC (American Type CultureCollection, Rockville, USA). The cells were cultured in DMEM (Dulbecco'smodified Eagle's medium) supplemented with 10% fetal bovine serum (FBS)in a 37° C. CO₂ incubator with 95% humidity.

<1-2> Measurement of the Expression of Osteoprotegerin Inhibiting theGeneration of Osteoclasts

The present inventors investigated whether the level of OPG wasincreased by treating the extract obtained in Example 1 to the cultureof osteoblasts.

MG-63 cells, prepared in the above Experimental Example <1-1>, werecultured in a 96-well plate until confluented. The plate was treatedwith 2 ml of serum free DMEM containing the herbal mixture extract withvarious concentrations, followed by further culturing for 16 hours.Supernatant was obtained. The level of OPG was measured by ELISA.Optocal density (O.D.) was measured by using Dynatech MR-7000 (DynatechLaboratorie) at 450 nm and the amount of secreted OPG was calculated bypercentage for control treated only with medium according to the belowMathematical Formula 1.

<Mathematical Formula 1>Increase rate of OPG release (%)=(1−O.D. ₄₅₀ of experimental group/O.D.₄₅₀ of control group)100

(In the Formula, O.D.₄₅₀ means optical density at 450 nm)

As shown in Table 1, treatment of Rehmanniae Radix Preparata extract ofthe <example 1> with 3 and 6 mg/ml increased the expression of OPG, aprotein inhibiting the generation of osteoclasts, 200% and 221%respectively, and treatment of Acanthopanacis Cortex extract with 1.25mg/ml also increased the expression of OPG up to 194%, suggesting thattwo single herbal extracts increase OPG expression dose-dependently. Inthe meantime, when the herbal extracts were used as a mixture, OPG levelwas 120˜130% increased (Table 1, FIG. 1). OPG expression inducing effectof the herbal mixture extract was remarkably enhanced when RehmanniaeRadix Preparata extract and Acanthopanacis Cortex extract were mixedwith 3 mg/ml and 1.25 mg/ml respectively, compared with when RehmanniaeRadix Preparata extract was added by 6 mg/ml. The above results indicatethat the mixing ratio of Rehmanniae Radix Preparata extract andAcanthopanacis Cortex extract in the preparation of a herbal mixture isimportant to enhance OPG expression. TABLE 1 OPG secretion rate(%)Acanthopanacis Cortex extract Conc. (mg/ml) 0 1.25 Rehmanniae Radix 0100 194.8 Preparata 3 200.4 249.2 extract 6 221.6 198.2

From the above results, it was confirmed that the herbal mixture extractof the present invention increases the expression of OPG, a proteininhibiting the generation of osteoclasts, and thereby inhibits Patentthe generation of osteoclasts.

EXPERIMENTAL EXAMPLE 2 Osteoclast Generation Inhibitory Activity ofHerbal Mixture Extract of the Present Invention

To examine the effect of herbal mixture extract of the present inventionon the generation and activity of osteoclasts, osteoclast precursorcells were cultured in a calcium-phosphate coated plate (OAAS, OscotecInc.), followed by investigation of the activity of TRAP(tartrate-resistant acid phosphatase), an osteoclast marker.

<2-1> Isolation of Osteoclast Precursor Cells and Differentiation ofOsteoclast Precursor Cells into Mature Osteoclasts

To isolate mouse bone marrow cells, male mouse at 7-9 weeks old wassacrificed by cervical dislocation, then femur and tibia were extractedunder aseptic condition. Soft tissue was removed and both ends of bonewere cut out. 1 ml of an enzyme solution containing 0.1% collagenase(Gibco), 0.05% trypsin and 0.5 mM EDTA (Gibco) was flushed into one endof marrow cavity by using 26 G needle. Bone marrow was taken out,followed by stirring for 30 minutes. Bone marrow cells were recoveredand pre-cultured for 24 hours in α-MEM α-minimum essential medium)supplemented with 10% FBS. Unattached cells were obtained. Theunattached cells, osteoclast precursor cells, were seeded into a plate(2×10⁵ cells per well), followed by culture. The herbal mixture extractof the invention was treated to α-MEM containing 20 ng/ml ofmacrophage-colony stimulating factor (M-CSF, Peprotech, USA) and 30ng/ml of RANKL (Peprotech, USA) during the 8-day of culture. Uponcompletion of the culture, cells were fixed and TRAP staining wasperformed to examine the generation of osteoclasts.

<2-2> Formation of TRAP(+) Multinucleated Cells (MNCs)

To examine the generation of osteoclasts, osteoclast precursor cellswere cultured in calcium-phosphate coated plate and then TRAP (+) MNCswere counted.

Particularly, upon completion of cell culture, attached cells werewashed with PBS and fixed with citrate-acetate-formaldehyde for 5minutes. The cells were further cultured in 37° C. acetate buffer(pH5.0) containing naphthol AS-BI phosphate, fast Garnet GBC solutionand 7 mM tartrate buffer (pH 5) for one hour, followed by staining withTRAP. TRAP(+) MNCs having more than 3 nuclei were considered asosteoclasts. The herbal mixture extract prepared in Example 1 and eachsingle extract were treated to the cells. After 8 days of culture,TRAP(+) MNCs were counted again and osteoclast generation inhibitingrate was calculated thereby according to the below Mathematical Formula2.

<Mathematical Formula 2>TRAP(+) MNCs gengration inhibition rate (%)=100−(Number of TRAP(+) MNCsof experimental group/Number of TRAP(+) MNCs of control group)×100 TABLE2 Osteoclast generation inhibition rate (%) Acanthopanacis Cortexextract Conc. (mg/ml) 0 0.125 0.25 000.5 1 Rehmanniae 0 0.00 12.77 19.2861.61 99.74 Radix 0.125 12.43 15.85 33.42 70.69 99.57 Preparata 0.2512.68 28.19 40.10 71.64 99.83 extract 0.5 40.10 40.02 60.84 81.92 100.001 49.01 55.01 68.98 93.32 100.00 2 81.75 90.15 92.89 99.31 100.00

As shown in Table 2 and FIG. 2, osteoclast generation inhibiting rate ofcontrol group treated no extract was considered 0, and based on that,osteoclast generation inhibiting rates of each experimental grouptreated with different extracts with different concentrations werecompared. The TRAP(+) MNCs generation inhibition rates were 12.43,12.68, 40.10, 49.01 and 81.75% at the concentration of 0.125, 0.25, 0.5,1 and 2 mg/ml, respectively, when Rehmanniae Radix Preparata extract wasindependently treated. In the meantime, when Acanthopanacis Cortexextract was independently treated, the generation and activation ofosteoclasts were inhibited 12.77, 19.28, 61.61 and 99.74% at theconcentration of 0.125, 0.25, 0.5 and 1 mg/ml respectively, suggestingthat the independent treatment of each herbal extract inhibited TRAP(+)MNCs generation dose-dependently.

While Rehmanniae Radix Preparata extract showed no more than 50%inhibiting effect at the concentration of up to 0.5 mg/ml, or even withincreasing the concentration, the co-treatment of Rehmanniae RadixPreparata extract with Acanthopanacis Cortex extract displayed 100%inhibiting effect even at low concentration. The formation ofosteoclasts was remarkably inhibited when Rehmanniae Radix Preparataextract and Acanthopanacis Cortex extract were mixed with more than 0.25mg/ml each, in particular when Rehmanniae Radix Preparata extract wasincluded more than 20 weight % and Acanthopanacis Cortex extract wasincluded more than 10 weight %, more preferably when Rehmanniae RadixPreparata extract was included more than 50 weight % and AcanthopanacisCortex extract was included more than 25 weight %. When the contents ofthose extracts were less than the above range, osteoclast generation wasnot that much inhibited.

Therefore, it was confirmed that the herbal mixture extract of thepresent invention inhibits the generation and activation of osteoclastsbetter than each independent herbal extract, Rehmanniae Radix Preparataextract and Acanthopanacis Cortex extract, can do.

EXPERIMENTAL EXAMPLE 3 Acute Toxicity in Rats Tested via OralAdministration

The following experiments were performed to see if the herbal mixtureextracts of the present invention have acute toxicity in rats.

6-week old specific pathogen-free (SPF) SD rats were used in the testsfor acute toxicity. The herbal mixture extract of the present inventionwas suspended in 0.5% methylcellulose solution and orally administeredonce to 2 rats per group at the dosage of 1 g/kg/ml. Death, clinicalsymptoms and weight change in mice were observed, hematological testsand biochemical tests of blood were performed, and any abnormal signs inthe gastrointestinal organs of chest and abdomen were checked with eyesduring autopsy.

The results showed that the herbal mixture extract of the presentinvention did not cause any specific clinical symptoms, weight change ordeath in rats. No change was observed in hematological tests,biochemical tests of blood and autopsy.

Therefore, the herbal mixture extract used in this experiment wasevaluated to be safe substance since it did not cause any toxic changein rats up to the level of 1 g/kg and its estimated LD₅₀ values are muchgreater than 1 g/kg in mice.

The Manufacturing Examples of the composition for the present inventionare described hereinafter.

MANUFACTURING EXAMPLE 1 Preparation of Pharmaceutical Formulations

<1-1> Preparation of Powders Herbal mixture extract of the presentinvention 2 g Lactose 1 g

Powders were prepared by mixing all the above components and filledairtight bag with them.

<1-2> Preparation of Tablets Herbal mixture extract of the presentinvention 100 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate  2mg

Tablets were prepared by mixing all the above components by theconventional method for preparing tablets.

<1-3> Preparation of Capsules Herbal mixture extract of the presentinvention 100 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate  2mg

Capsules were prepared by mixing the components above and filled gelatincapsules with them according to the conventional method for capsules.

MANUFACTURING EXAMPLE 2 Preparation of Food

Foodstuff containing the herbal mixture extract of the present inventionwas prepared as follows.

<2-1> Preparation of Flour Food

Health improving flour food was prepared by adding the herbal mixtureextract of the present invention by 0.5˜5.0 weight % to wheat flour andthen making the flour into bread, cakes, cookies, crackers and noodles.

<2-2> Preparation of Dairy Products

The herbal mixture extract of the present invention was added by 5˜10weight % to milk to prepare health improving dairy products such asbutter, ice cream, etc.

<2-3> Preparation of Sunsik

Brown rice, barley, glutinous rice and coix (job's tear) weregelatinizated by the conventional method, followed by drying. The driedmixture was distributed and pulverized, resulting in 60-mesh size grainpowders.

Black bean, black sesame and perilla were steamed and dried by theconventional method. The dried mixture was distributed and pulverized,resulting in 60-mesh size grain powders.

The herbal mixture extract of the present invention wasvacuum-concentrated under reduced pressure using a vacuum concentrator,which was then spray-dried with a hot-air drier. The dried material waspulverized by a grinder, resulting in 60-mesh size grain powders.

The prepared grain, seeds, and dried herbal mixture extract powders wereall mixed at the following ratio.

Grain (brown rice 30 weight %, coix 15weight %, barley 20weight %),

Seeds (perilla 7 weight %, black bean 8 weight %, black sesame 7 weight%),

Dried powder of herbal mixture extract (3 weight %),

Ganoderma lucidum (0.5 weight %),

Rehmannia glutinosa (0.5 weight %)

MANUFACTURING EXAMPLE 3 Preparation of Beverages

<3-1> Preparation of Carbonated Beverages

Sugar (5˜10%), citric acid (0.05˜0.3%), caramel (0.005˜0.02%) andvitamin C (0.1˜1%) were mixed, to which purified water (79˜94%) wasadded to make syrup. The prepared syrup was sterilized at 85˜98° C. for20-180 seconds, then mixed with cooling water at the ratio of 1:4. Then,carbon dioxide gas (0.5˜0.82%) was given to the mixture to preparecarbonated beverages containing the herbal mixture extract of thepresent invention.

<3-2> Preparation of Health Beverages

Acid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) andwater (75%) were all mixed with the herbal mixture extract of thepresent invention evenly, followed by sterilization. The was put in asmall container such as a glass bottle or pat resulting in healthbeverages.

<3-3> Preparation of Vegetable Juice

5 g of the herbal mixture extract of the present invention was added to1,000 ml of tomato or carrot juice to prepare health vegetable juice.

<3-4> Preparation of Fruit Juice

1 g of the herbal mixture extract of the present invention was added to1,000 ml of apple or grape juice to produce health fruit juice.

INDUSTRIAL APPLICABILITY

As described hereinbefore, the herbal mixture extract of RehmanniaeRadix Preparata and Acanthopanacis Cortex of the present invention haseffects of inhibiting the generation and activation of osteoclasts byenhancing the expression of osteoprotegerin in osteoblasts andinhibiting the generation of osteoclasts, thereby. In particular, whenthe mixture contains Rehmanniae Radix Preparata extract more than 20weight % and Acanthopanacis Cortex extract more than 10 weight %, morepreferably when the mixture contains Rehmanniae Radix Preparata extractmore than 50 weight % and Acanthopanacis Cortex extract more than 25weight %, the inhibiting effects were remarkably enhanced, compared withwhen each extract was treated independently. Thus, the herbal mixtureextract of the invention, owing to its synergy effect, can effectivelyused for the prevention and treatment of osteoporosis as medicinal agentand health food.

Those skilled in the art will appreciate that the conceptions andspecific embodiments disclosed in the foregoing description may bereadily utilized as a basis for modifying or designing other embodimentsfor carrying out the same purposes of the present invention. Thoseskilled in the art will also appreciate that such equivalent embodimentsdo not depart from the spirit and scope of the invention as set forth inthe appended claims.

1. An herbal mixture extract of Rehmanniae Radix Preparata andAcanthopanacis Cortex.
 2. The herbal mixture extract as set forth inclaim 1, in which Rehmanniae Radix Preparata extract and AcanthopanacisCortex extract are mixed at the weight ratio of 15.0:0.5˜0.15:5.0. 3.The herbal mixture extract as set forth in claim 1, in which RehmanniaeRadix Preparata extract and Acanthopanacis Cortex extract are mixed atthe weight ratio of 8:1˜1:4.
 4. The herbal mixture extract as set forthin claim 1, in which Rehmanniae Radix Preparata extract andAcanthopanacis Cortex extract are mixed at the weight ratio of 4:1˜1:1.5. The herbal mixture extract as set forth in claim 2, in which theRehmanniae Radix Preparata extract is extracted using Rehmanniae RadixPreparata with water, C₁˜C₄ alcohol or their mixture.
 6. The herbalmixture extract as set forth in claim 2, in which the AcanthopanacisCortex extract is extracted using Acanthopanacis Cortex with water,C₁˜C₄ alcohol or their mixture.
 7. An accelerant of osteoprotegerin(OPG) expression in osteoblasts containing the herbal mixture extract ofclaim 1 as an effective ingredient.
 8. An inhibitor of osteoclastgeneration containing the herbal mixture extract of claim 1 as aneffective ingredient.
 9. A composition for the prevention and treatmentof osteoporosis containing the herbal mixture extract of claim 1 as aneffective ingredient.